Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
A new study by Sandra Amaral and her team has found that children with chronic kidney disease (CKD), regardless of disease severity,...
Read Full NewsSubcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.
Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.
A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.
1.
According to a study, taking part in a clinical trial for cancer may not actually increase survival.
2.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
3.
Efanesoctocog Alfa Prevented Bleeding in Kids With Severe Hemophilia A
4.
A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials
5.
Higher Risk of Kidney Cancer Recurrence After Ablative Therapy
1.
Understanding Dasatinib: A Promising Drug for Cancer Treatment
2.
Uncovering the Reality of Colon Cancer: A Look at Real Images
3.
Everything You Need to Know About Normal Potassium Levels
4.
The Journey Beyond Treatment: Empowering Cancer Survivorship with Technology and Artificial Intelligence
5.
Understanding QSOFA: A Vital Tool for Recognizing Sepsis
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
3.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
4.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge